Lifeward receives FDA clearance for ReWalk 7 exoskeleton
Evidence notes
- Lifeward received 510(k) FDA clearance for the ReWalk 7 personal exoskeleton.
- The seventh-generation ReWalk device is designed for individuals with spinal cord injury.
- The clearance followed prior FDA clearance for ReWalk stair and curb functionality and CMS national reimbursement policy development.
Company context
Lifeward, formerly ReWalk Robotics, develops wearable robotic exoskeletons and rehabilitation technologies for people with mobility impairments.